Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oxymetazoline Clear all
Not listed Phase 1 Interventional Accepts healthy volunteers

Intra-anal Oxymetazoline in Healthy Adult Volunteers

NCT03529487
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Oxymetazoline
Drug
Lead sponsor
RDD Pharma Ltd
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet

NCT01640093
View directory record Official record
Conditions
Healthy Participants
Interventions
Abiraterone acetate, 250 mg (uncoated, current commercial tablet), Abiraterone acetate, 500 mg (coated, reformulated tablet), Abiraterone acetate, 250 mg (coated, reformulated tablet), Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01454063
View directory record Official record
Conditions
Intraocular Lens Replacement
Interventions
OMS302, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
Chandler, Arizona • Glendale, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hyporeactivity and Gulf War Illness

NCT00100412
View directory record Official record
Conditions
Gulf War Syndrome, Chronic Fatigue Syndrome, Post-Traumatic Stress Disorder
Interventions
Graded dobutamine infusions, Graded phenylephrine injections, Psychosocial challenge involving socioevaluative public speaking
Drug · Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2002
U.S. locations
1
States / cities
East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin

NCT01081353
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Acetylsalicylic Acid (Aspirin BAY1019036), Alka Seltzer Extra Strength, Aspirin Migraine, Aspirin Aspro
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TransMEM Gas Exchange -- Project 1, Aim 2

NCT01925729
View directory record Official record
Conditions
Middle Ear Disease, Nasal Allergy
Interventions
ragweed, histamine, pseudoephedrine, Oxymetazoline
Biological · Drug
Lead sponsor
Cuneyt M. Alper
Other
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients

NCT06366217
View directory record Official record
Conditions
Dilation, Pupil Reaction Absent
Interventions
MydCombi Device, MydCombi Drug
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 29, 2026, 5:40 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Characterization of Sympathetic Nerve Activity in Stress Cardiomyopathy

NCT01048125
View directory record Official record
Conditions
Cardiomyopathy
Interventions
Sympathetic Nerve Activity, Mental Stress Test (Color Word Test), The Modified Oxford Technique for Baroreflex Sensitivity, Cold Pressor Test, Echocardiographic evaluation
Device · Behavioral · Drug + 1 more
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 2 Interventional

Induced Hypertension for Acute Ischemic Stroke

NCT00227448
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
intravenous saline, intravenous phenylephrine, intravenous levophed, oral midodrine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

NCT05223478
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Longwood, Florida • Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2023 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation

NCT01080612
View directory record Official record
Conditions
Healthy
Interventions
330 mg pregabalin controlled release, 300 mg pregabalin immediate release
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

NCT01289509
View directory record Official record
Conditions
Idiopathic Thrombocytopenia Purpura
Interventions
E5501, Drug: E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 4 Interventional Results available

No Drop Post-Op Cataract Surgery

NCT03864133
View directory record Official record
Conditions
Cataract
Interventions
Omidria
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 90 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

NCT02293148
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Not applicable Interventional

The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment

NCT00585091
View directory record Official record
Conditions
Heart Failure
Interventions
phenylephrine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Sep 29, 2026, 5:40 PM EDT
Not listed Phase 4 Interventional

Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery

NCT04602767
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Vasopressin, Phenylephrine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

NCT02018536
View directory record Official record
Conditions
Healthy
Interventions
GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 2 Interventional Results available

The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope

NCT04972123
View directory record Official record
Conditions
Syncope, Vasovagal
Interventions
CPC - Capsaicin, Phenylephrine, Caffeine, Tilt Table Test, Placebo
Drug · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval

NCT02165332
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Part 1: SAD RO7033877, Part 1: SAD placebo, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877, Part 2: Treatment C, moxifloxacin, Part 2: Treatment D, RO7033877 and moxifloxacin placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers

NCT06137703
View directory record Official record
Conditions
Biological Availability
Interventions
Zavegepant 100mg non-enteric coated soft gel capsule, Zavegepant 100mg immediate release tablet, Zavegepant 2 x 100mg immediate release tablets, Zavegepant 4 x 25mg enteric coated soft gel capsule
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 29, 2026, 5:40 PM EDT
Terminated Not applicable Interventional

Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion

NCT00584662
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
Oxymetazoline Hydrochloride
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effect of Food on the Bioavailability of PN400 Components

NCT00676442
View directory record Official record
Conditions
Arthritis
Interventions
PN400
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2008 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers

NCT01045083
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO4917523, escitalopram, methylphenidate, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 29, 2026, 5:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Comparison Study of Pain Relief From Dysmenorrhea Between the Vipon Tampon and Ibuprofen

NCT00951561
View directory record Official record
Conditions
Dysmenorrhea
Interventions
Vipon, Ibuprofen
Device · Drug
Lead sponsor
Another Way Products
Industry
Eligibility
18 Years and older · Female only
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 15, 2011 · Synced Sep 29, 2026, 5:40 PM EDT